Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix.

ABSTRACT:

Objective

To evaluate the effects of elagolix on clinically meaningful improvements in health-related quality of life (HRQOL) measured by the EHP-30 (Endometriosis Health Profile-30).

Methods

Data from two phase III trials of elagolix for moderate to severe pain associated with endometriosis were pooled and analyzed as three groups: placebo, elagolix 150 mg once daily, or elagolix 200 mg twice daily. Patients were administered the EHP-30 questionnaire at baseline, and at months 1, 3, and 6 of treatment. Previously established responder definitions were applied to determine percentages of patients with clinically meaningful EHP-30 improvements. The probability of meeting EHP-30 responder definitions with elagolix compared with placebo at months 3 and 6 was determined by Poiss

SUBMITTER: Taylor HS 

PROVIDER: S-EPMC7431150 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature